The clinical-stage immuno-oncology company expects to dose the first patient in early 2022.
About 100 patients will be randomized to receive either SRF388 or a placebo in combination with atezolizumab and bevacizumab. Surface Oncology anticipates a futility analysis in early 2023 and final data in H1 2024, it said.
The company also said it has expanded its debt facility with K2 HealthVentures to $50 million and maintains a projected cash runway through 2023.
Price: 7.90, Change: 0.00, Percent Change:
|Goldman Sachs Upgrades GitLab to Buy From Neutral, A...|
|Goldman Sachs Adjusts Price Target on Lowe's to $205...|
|Goldman Sachs Adjusts Ulta Beauty's Price Target to ...|
|--Street Color: May preliminary capital goods shipme...|
|--Street Color: May preliminary capital goods orders...|